EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in First-Line Metastatic NSCLC

Opinion
Video

Thoracic oncologists discuss the EVOKE-02 study investigating sacituzumab govitecan in combination with pembrolizumab in patients with first-line metastatic NSCLC.

Related Videos
Related Content